DDInter837 DDInter1676
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diiodohydroxyquinoline
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Cyclophosphamide
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Golimumab may lead to a major life threatening interaction when taken with Cyclophosphamide
Golimumab may lead to a major life threatening interaction when taken with Avapritinib